193 related articles for article (PubMed ID: 18575766)
1. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
2. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hirakawa A; Ono M; Kouno T; Katsumata N; Ando M; Tamura K; Hasegawa T; Kinoshita T; Fujiwara Y
J Surg Oncol; 2010 Mar; 101(3):222-7. PubMed ID: 20087905
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract][Full Text] [Related]
5. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
6. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J
Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460
[TBL] [Abstract][Full Text] [Related]
8. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract][Full Text] [Related]
9. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Memon AA; Sorensen SB; Nexo E
Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
11. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
12. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
Lee CM; Shrieve DC; Zempolich KA; Lee RJ; Hammond E; Handrahan DL; Gaffney DK
Gynecol Oncol; 2005 Nov; 99(2):415-21. PubMed ID: 16157365
[TBL] [Abstract][Full Text] [Related]
13. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
[TBL] [Abstract][Full Text] [Related]
14. Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro.
Patel NV; Acarregui MJ; Snyder JM; Klein JM; Sliwkowski MX; Kern JA
Am J Respir Cell Mol Biol; 2000 Apr; 22(4):432-40. PubMed ID: 10745024
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
Campiglio M; Ali S; Knyazev PG; Ullrich A
J Cell Biochem; 1999 Jun; 73(4):522-32. PubMed ID: 10733345
[TBL] [Abstract][Full Text] [Related]
16. The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
[TBL] [Abstract][Full Text] [Related]
17. Low expression of HER2 protein in breast cancer is biologically significant.
Tovey SM; Reeves JR; Stanton P; Ozanne BW; Bartlett JM; Cooke TG
J Pathol; 2006 Nov; 210(3):358-62. PubMed ID: 16981252
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma.
Fuchs I; Vorsteher N; Bühler H; Evers K; Sehouli J; Schaller G; Kümmel S
Anticancer Res; 2007; 27(2):959-63. PubMed ID: 17465227
[TBL] [Abstract][Full Text] [Related]
19. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
20. High expression of HER3 is associated with a decreased survival in gastric cancer.
Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
